Testing for ROS1 in non-small cell lung cancer: a review with recommendations

Rearrangements of the ROS1 gene occur in 1–2 % of non-small cell lung cancers (NSCLCs). Crizotinib, a highly effective inhibitor of ROS1 kinase activity, is now FDA-approved for the treatment of patients with advanced ROS1-positive NSCLC. Consequently, focus on ROS1 testing is growing. Most laborato...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Virchows Arch
Autores principales: Bubendorf, Lukas, Büttner, Reinhard, Al-Dayel, Fouad, Dietel, Manfred, Elmberger, Göran, Kerr, Keith, López-Ríos, Fernando, Marchetti, Antonio, Öz, Büge, Pauwels, Patrick, Penault-Llorca, Frédérique, Rossi, Giulio, Ryška, Aleš, Thunnissen, Erik
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Berlin Heidelberg 2016
Materias:
Review and Perspectives
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5082594/
https://ncbi.nlm.nih.gov/pubmed/27535289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00428-016-2000-3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares